Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Other Non-Current Liabilities (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Other Non-Current Liabilities readings, the most recent being $1.7 million for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 13.96% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 13.96% year-over-year, with the annual reading at $1.7 million for FY2025, 13.96% up from the prior year.
  • Other Non-Current Liabilities hit $1.7 million in Q4 2025 for Terns Pharmaceuticals, up from $1.6 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $1.7 million in Q4 2025 and bottomed at $654000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $1.1 million, with a median of $1.1 million recorded in 2023.
  • The largest annual shift saw Other Non-Current Liabilities grew 6.62% in 2022 before it skyrocketed 56.84% in 2023.
  • Terns Pharmaceuticals' Other Non-Current Liabilities stood at $787000.0 in 2021, then soared by 36.09% to $1.1 million in 2022, then rose by 12.61% to $1.2 million in 2023, then rose by 23.55% to $1.5 million in 2024, then increased by 13.96% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Other Non-Current Liabilities are $1.7 million (Q4 2025), $1.6 million (Q3 2025), and $1.6 million (Q2 2025).